Sharon M Weber, MD, FACS


  • Chief, Division of Surgical Oncology
  • Medical Director of Surgical Oncology, UW Carbone Cancer Center
  • Endowed Professor, Tim and Mary Ann McKenzie Professorship in Surgical Oncology
Clinic: (608) 263-7502

  • Administrative Assistant: (608) 262-2025

600 Highland Avenue
Box 7375 Clinical Science Center
Madison, Wisconsin 53792-3284


  • MD, University of Wisconsin Medical School, Madison, WI, 1993
  • Residency in General Surgery, University of Wisconsin Hospital and Clinics, Madison, WI, 1993-1999
  • Research Fellowship in Tumor Immunotherapy, University of Wisconsin Medical School, Madison, WI, 1996-1997
  • Surgical Oncology Fellowship, Memorial Sloan-Kettering Cancer Center, New York, NY, 1999-2001
  • Hepatobiliary Fellowship, Memorial Sloan-Kettering Cancer Center, New York, NY, 2000-2001

Clinical Specialties

Dr. Weber is actively involved in minimally invasive approaches to cancer treatment, including both laparoscopic pancreas and liver surgery. She has been invited as a speaker/moderator at many national meetings, including the American College of Surgeons, the American Hepatopancreaticobiliary Association, Society of Surgical Oncology, and Society of University Surgeons.

Research Interests

Dr. Weber conducts translational research at the UW Carbone Cancer Center evaluating novel tumor selective agents which may be promising for imaging and/or treating tumors. She also conducts clinical research evaluating prognosticators of outcome in patients with liver, bile duct, and liver tumors. Dr. Weber’s research interests also include mixed methods evaluation of risk factors for readmission using a systems engineering approach with a focus on the transition of care and outcomes research evaluating preoperative predictors of postoperative complications.

Recent Publications

  • What Drives High Costs of Cytoreductive Surgery and HIPEC: Patient, Provider or Tumor?
    Schwartz PB, Stahl CC, Vande Walle KA, Pokrzywa CJ, Cherney Stafford LM, Aiken T, Barrett J, Acher AW, Leverson G, Ronnekleiv-Kelly S, Weber SM, Abbott DE
    Ann. Surg. Oncol. 2020 May 15;
    [PubMed ID: 32415351]

  • Current Advances in Minimally Invasive Surgical Management of Perihilar Cholangiocarcinoma.
    Rahnemai-Azar AA, Abbasi A, Tsilimigras DI, Weber SM, Pawlik TM
    J. Gastrointest. Surg. 2020 May 14;
    [PubMed ID: 32410178]

  • Correction to: Trends in the Number of Lymph Nodes Evaluated Among Patients with Pancreatic Neuroendocrine Tumors in the United States: A Multi-Institutional and National Database Analysis.
    Sahara K, Tsilimigras DI, Mehta R, Moro A, Paredes AZ, Lopez-Aguiar AG, Rocha F, Kanji Z, Weber S, Fisher A, Fields RC, Krasnick BA, Idrees K, Smith PM, Poultsides GA, Makris E, Cho C, Beems M, Dillhoff M, Maithel SK, Endo I, Pawlik TM
    Ann. Surg. Oncol. 2020 Apr 27;
    [PubMed ID: 32342296]

  • Summary perioperative risk metrics within the electronic medical record predict patient-level cost variation in pancreaticoduodenectomy.
    Stahl CC, Schwartz PB, Leverson GE, Barrett JR, Aiken T, Acher AW, Ronnekleiv-Kelly SM, Minter RM, Weber SM, Abbott DE
    Surgery 2020 Apr 26;
    [PubMed ID: 32349869]

  • Adjuvant therapy following resection of gastroenteropancreatic neuroendocrine tumors provides no recurrence or survival benefit.
    Barrett JR, Rendell V, Pokrzywa C, Lopez-Aguiar AG, Cannon J, Poultsides GA, Rocha F, Crown A, Beal E, Michael Pawlik T, Fields R, Panni RZ, Smith P, Idrees K, Cho C, Beems M, Maithel S, Weber S, Erik Abbott D
    J Surg Oncol 2020 Jun; 121(7): 1067-1073
    [PubMed ID: 32153032]

All Publications on PubMed